Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
9.61
-0.16 (-1.64%)
At close: Jul 11, 2025, 4:00 PM
9.60
-0.01 (-0.10%)
After-hours: Jul 11, 2025, 5:47 PM EDT
Avadel Pharmaceuticals Employees
Avadel Pharmaceuticals had 188 employees as of December 31, 2024. The number of employees increased by 34 or 22.08% compared to the previous year.
Employees
188
Change (1Y)
34
Growth (1Y)
22.08%
Revenue / Employee
$1,034,309
Profits / Employee
-$140,479
Market Cap
931.21M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AVDL News
- 11 days ago - ASL pushes for board shakeup at Avadel over handling of sleep drug rollout - Reuters
- 11 days ago - ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders - Business Wire
- 11 days ago - Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation - GlobeNewsWire
- 12 days ago - ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reports - Reuters
- 12 days ago - An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure - WSJ
- 25 days ago - Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia - GlobeNewsWire
- 6 weeks ago - Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025 - GlobeNewsWire